文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

纳武利尤单抗在脓毒症诱导免疫抑制患者中的药代动力学、药效学与安全性:多中心、开放标签1/2期研究

Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study.
PubMed 文献 · Shock · 2020-01-01
一句话结论日本多中心1/2期研究显示,单次静脉输注960 mg纳武利尤单抗在脓毒症诱导免疫抑制患者中似乎耐受良好,且足以维持血药浓度。

该多中心、开放标签1/2期研究纳入日本脓毒症诱导免疫抑制患者,分别单次静脉输注480 mg(5例)或960 mg(8例)纳武利尤单抗,剂量选择旨在模拟癌症患者获批剂量3 mg/kg每2周所达到的暴露。480 mg后最大浓度132 μg/mL,与3 mg/kg每2周输注结束时预测浓度117 μg/mL相似;960 mg后第28天浓度33.1 μg/mL,落在3 mg/kg每2周预测谷浓度范围(90%预测区间19.0-163 μg/mL)内。绝对淋巴细胞计数和单核细胞人类白细胞抗原-DR亚型表达水平似乎随时间升高。480 mg组和960 mg组不良事件发生率分别为80%和50%,仅480 mg组1例发生药物相关不良事件,无纳武利尤单抗相关死亡。作者认为,单次960 mg纳武利尤单抗似乎耐受良好且足以维持血药浓度,480 mg和960 mg似乎均随时间改善免疫系统指标。

要点

  • 日本多中心1/2期研究:脓毒症诱导免疫抑制患者单次静脉输注纳武利尤单抗480 mg(5例)或960 mg(8例)。
  • 480 mg后最大浓度132 μg/mL,与3 mg/kg每2周输注结束时预测浓度117 μg/mL相似。
  • 960 mg后第28天浓度33.1 μg/mL,在3 mg/kg每2周预测谷浓度90%预测区间19.0-163 μg/mL内。
  • 不良事件发生率480 mg组80%、960 mg组50%,仅480 mg组1例药物相关不良事件,无纳武利尤单抗相关死亡。
  • 绝对淋巴细胞计数和单核细胞人类白细胞抗原-DR亚型表达水平似乎随时间升高。

适用人群与场景

  • 日本脓毒症诱导免疫抑制患者,接受单次静脉输注纳武利尤单抗480 mg(5例)或960 mg(8例)。

处置流程与药物剂量

  • 纳武利尤单抗单次480 mg或960 mg静脉输注;剂量选择旨在模拟癌症患者获批剂量3 mg/kg每2周所达到的暴露。

研究设计与关键结果

  • 多中心、开放标签1/2期研究:480 mg组5例、960 mg组8例脓毒症诱导免疫抑制的日本患者,单次静脉输注纳武利尤单抗。
  • 480 mg后最大浓度132 μg/mL,与3 mg/kg每2周输注结束时预测浓度117 μg/mL相似。
  • 960 mg后第28天浓度33.1 μg/mL,在3 mg/kg每2周预测谷浓度90%预测区间19.0-163 μg/mL内。
  • 绝对淋巴细胞计数和单核细胞人类白细胞抗原-DR亚型表达水平似乎随时间升高。
  • 不良事件发生率480 mg组80%、960 mg组50%;药物相关不良事件仅480 mg组1例;无纳武利尤单抗相关死亡。

证据类型、等级与局限

  • 证据类型:多中心、开放标签1/2期研究。
  • 作者结论:单次960 mg纳武利尤单抗似乎耐受良好且足以维持血药浓度;480 mg和960 mg似乎均随时间改善免疫系统指标。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,单次960 mg纳武利尤单抗似乎耐受良好且足以维持血药浓度;480 mg和960 mg似乎均随时间改善免疫系统指标。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sepsis often induces an immunosuppressive state, which is associated with high mortality rates. Immunostimulation may be beneficial for sepsis. We investigated the pharmacokinetics, pharmacodynamics, and safety of nivolumab, a human programmed death-1 immune checkpoint inhibitor approved for the treatment of several cancers.

METHODS: In this multicenter, open-label phase 1/2 study, a single 480 or 960 mg nivolumab dose was intravenously infused into Japanese patients with immunosuppressive sepsis. Doses were selected to mimic the exposure achieved with the approved dosage for cancer patients (3 mg/kg every 2 weeks [Q2W]).

RESULTS: Single 480 and 960 mg nivolumab doses were intravenously infused into five and eight patients, respectively. The maximum concentration after 480 mg (132 μg/mL) was similar to the predicted concentration at the end of infusion with 3 mg/kg Q2W (117 μg/mL). The concentration on Day 28 after 960 mg (33.1 μg/mL) was within the predicted trough concentration range for 3 mg/kg Q2W (90% prediction interval 19.0-163 μg/mL). Absolute lymphocyte counts and monocyte human leukocyte antigen-DR subtype expression levels appeared to increase over time. The incidences of adverse events (AEs) were 80% and 50% in the 480 mg and 960 mg groups, respectively. Drug-related AEs were observed in only one patient in the 480 mg group. No deaths related to nivolumab occurred.

CONCLUSIONS: A single dose of 960 mg nivolumab appeared to be well tolerated and sufficient to maintain nivolumab blood concentrations. Both 480 mg and 960 mg nivolumab seemed to improve immune system indices over time.

TRIAL REGISTRATION: JAPIC, JapicCTI-173600.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Watanabe E, Nishida O, Kakihana Y, et al. Pharmacokinetics, Pharmacodynamics, and Safety of Nivolumab in Patients With Sepsis-Induced Immunosuppression: A Multicenter, Open-Label Phase 1/2 Study. Shock. 2020. PMID: 31513050. doi:10.1097/SHK.0000000000001443

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。